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Abstract
Red microalgal polysaccharides significantly inhibited the production of retroviruses (murine
leukemia virus- MuLV) and cell transformation by murine sarcoma virus(MuSV-124) in cell culture.
The most effective inhibitory effect of these polysaccharides against both cell transformation and
virus production was obtained when the polysaccharide was added 2 h before or at the time of
infection. Although, addition of the polysaccharide post-infection significantly reduced the number
of transformed cells, but its effect was less marked than that obtained when the polysaccharide was
added before or at the time of infection.The finding that the inhibition of cell transformation by
MuSV-124 was reversible after removal of the polysaccharide suggested that microalgal
polysaccharides inhibited a late step after provirus integration into the host genome. In conclusion,
our findings could support the possibility that the polysaccharide may affect early steps in the virus
replication cycle, such as virus absorption into the host cells, in addition to its effect on a late step
after provirus integration.
Background
Retroviruses [1–3] – viruses that contain reverse tran-
scriptase, an RNA-directed DNA polymerase [4,5] – have
been implicated in various types of human and animal
leukemia's and other tumors. Although there are many
compounds that exhibit potent anti-viral, and possibly
anti-tumor, activity in cell culture and in experimental an-
imals, only very few synthetic compounds and one natu-
ral product – alpha interferon – have so far been approved
for treatment of viral infections in man. Alpha interferon
has been approved for treatment of hairy cell leukemia, of
Karposi's sarcoma and of genital warts caused by papilo-
ma virus [6].
A class of natural products with low mammalian toxicity
that are currently regarded as having antitumor activity are
polysaccharides of biological origin, e.g., polysaccharides
from yeasts, algae, bacteria, higher plants and fungi [7–9].
Of interest in this context are polysaccharides produced
by some species of red algae; these compounds have
shown promising activity against a variety of animal virus-
es [10–13]. In general, polysaccharides exhibiting antivi-
ral potential are highly sulfated [10,14–17]. Dextran
sulfate and polysaccharides from marine algae, for exam-
ple, have been found to be potent in vitro inhibitors of
HIV types 1 and 2 [15,18–20]. They inhibit HIV-1-in-
duced cytopathogenicity and HIV-1 antigen expression
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[13,18,21,22]. These sulfated polysaccharides also inhibit
the activity of purified reverse transcriptase and RNase H,
which are essential for retrovirus replication [18,20].
Some previous studies showed that algal polysaccharides
exert their inhibitory action at a very early stage (adsorp-
tion, fusion or penetration), in the viral infection cycle
[9,18,20,23–25], whereas others showed that these
polysaccharides did not interfere with virus attachment or
penetration, but they did prevent viral protein synthesis
[11,26,27].
Our previous research has shown potent antiviral activity
of a highly sulfated polysaccharide extracted from red
microalga. The polysaccharide, which consists mainly of
xylose, glucose and galactose [28], exhibits antiviral activ-
ity against various members of the herpes family of viruses
[29]. In the current study, the activity of this red micro-
algal polysaccharide against the replication and the trans-
forming ability of the retroviruses, Moloney murine
sarcoma virus (MuSV) and Moloney murine leukemia vi-
rus (MuLV), was studied.
Results and Discussion
Characterization of cell transformation by MuSV-124 and 
MuSV/MuLV
NIH/3T3 cells grown in plastic dishes in RPMI medium
with 2% NBCS appear as flat cells (Fig 1a); these cells are
completely unable to grow in agar. When these cells were
infected with an appropriate dilution of MuSV-124, tiny
foci of transformed cells, with a highly refractile spindle
shape, growing randomly in a criss-cross fashion, could be
detected by microscopic observation within five days of
infection (Fig. 1b). Later, these foci gradually increased in
size and compactness until they became visible to the na-
ked eye on day 12 to 14 after infection with MuSV-124.
The number of foci remained unchanged in these cultures
during the entire culture period. When the cells were in-
fected with high titer of MuSV-124 (1 ffu/cell), most of the
cells were transformed two-three days after infection. In
MuSV/MuLV-infected cultures, the number of foci in-
creased continuously, and at any time foci of various sizes
(tiny to large) could be detected. Moreover, if these cul-
tures were maintained for a sufficiently long time, all the
cells eventually became transformed. Examination of the
culture medium for the presence of viral reverse tran-
scriptase revealed that MuSV/MuLV infection yielded vi-
rus-producing cells, whereas MuSV-124 infection resulted
in the formation of transformed cells not producing virus.
It is therefore likely that the increasing number of foci in
the productively infected cells resulted from multiple sec-
ondary infections by the virus progenies, the smaller foci
being formed by these infections. It was found that the lat-
er the infection, the smaller the foci. Both MuSV-124- and
MuSV/MuLV-transformed cells could grow efficiently in
agar.
Antiretroviral effect of red microalgal polysaccharides
The polysaccharide extracted from Porphyridium sp. was
more effective in inhibiting retrovirus replication and cell
transformation by MuSV than the polysaccharides ob-
tained from P. aerugineum or Rhodella reticulata (Table 1).
The concentration of Porphyridium sp. polysaccharide re-
quired for 50% protection against the formation of foci of
transformed cells by MuSV or for a 50% reduction in
MuLV production (as evaluated in terms of reverse tran-
scriptase activity) was one or two orders of magnitude
lower than that needed when P. aerugineum or R. reticulata
polysaccharide was applied. We therefore focused our re-
search on the anti-retroviral effects of Porphyridium sp.
polysaccharide.
Figure 1
(a) Control uninfected NIH/3T3 cells. (b) NIH/3T3 cells
infected and transformed by MuSV (5 days p.i.). The magnifi-
cation of these photos is × 40.
Table 1: Inhibiting effect of red microalgal polysaccharides on for-
mation of foci by MuSV-124 and on virus production, as measured 
by reverse transcriptase (RT) activity
Algal 
polysaccharide
Virus ffu50 protection 
(µg/ml)
RT50 reduction 
(µg/ml)
Porphyridium sp. MuSV-124 10 -
MuSV/MuLV - 5
P. aerugineum MuSV-124 500 -
MuSV/MuLV - 200
Rhodella reticulata MuSV-124 150 -
MuSV/MuLV - 50
NIH/3T3 cells were infected with MuSV-124 or MuSV/MuLV in the 
presence of various concentrations of algal polysaccharides. ffu50 pro-
tection and RT50 reduction represent the concentration of polysac-
charide that offers 50% protection against the formation of foci of 
malignant cells and 50% reduction of RT activity, respectively. Data 
represent mean values of five separate experiments.
 
 
a                                                     b 
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Porphyridium sp. polysaccharide was also superior to other
polysaccharides, such as carrageenan and dextran sulfate
500,000, in preventing the transformation of NIH/3T3
cells. Although the anti-transforming activity of Porphyrid-
ium sp. polysaccharide did not seem to be much higher
than that of carrageenan or dextran sulfate at a concentra-
tion of 10 µg/ml (Fig. 2), at the higher concentrations of
Porphyridium sp. polysaccharide was not toxic to the cells
whereas the other two biopolymers were extremely toxic
to the cells (Fig. 3). Porphyridium sp. polysaccharide had
no effect on the proliferation of NIH/3T3 cells, even up to
a concentration of 500 µg/ml (results not shown). How-
ever, at a concentration of 1,000 µg/ml, Porphyridium sp.
polysaccharide caused the cells to stop growing three days
after the beginning of the treatment (Fig. 3).
Microscopy showed that there were there were no changes
in cell morphology in the presence of Porphyridium sp.
polysaccharide, even at a concentration of 1000 µg/ml.
Effect of dosage of Porphyridium sp. polysaccharide on 
cell transformation
The algal polysaccharide significantly inhibited malignant
transformation of NIH/3T3 cells by MuSV or MuSV/
MuLV. As can be seen from Table 2, continuous treatment
with = 100 µg/ml of Porphyridium sp. polysaccharide,
from the time of infection until 14 days after infection
(scoring time), fully inhibited formation of foci by both
virus stocks.
Effect of time of addition of Porphyridium sp. polysaccha-
ride on cell transformation
The algal polysaccharide (100 µg/ml) was added to NIH/
3T3 cells at various times before and after infection with
either MuSV-124 or MuSV/MuLV. As can be seen from Ta-
ble 3, the polysaccharide fully inhibited formation of foci
in MuSV-124- and MuSV/MuLV-infected cultures if it was
added before or at the time of infection. If the polysaccha-
ride was added post-infection, it was less effective. In
MuSV/MuLV-infected cultures the polysaccharide was still
significantly inhibitory to the formation of foci when add-
ed 48 h after infection. The protective effect of the polysac-
charide in these cultures was lost only if it was added 72 h
after infection, whereas in MuSV-124-infected cultures the
effectiveness of the polysaccharide was lost when addition
was as early as 48 h after infection.
Figure 2
Kinetics of the development of MuSV-malignant cell
transformation in the presence of Porphyridium sp.
polysaccharide, dextran sulfate or carragenaan NIH/
3T3 cells were infected with 105 ffu of MuSV-124 in the
absence or presence of 10 µg/ml of Porhyridium sp. polysac-
charide (), dextran sulfate (♦ ) and carrageenan k (). The
treatment with the polysaccharide was continued up to the
end of the experiment. Data are mean ± SD, (n = 4).
Time p.i. (days)
0 2 4 6 8 1 01 21 4
%
T
r
a
n
s
f
o
r
m
e
d
 
c
e
l
s
 
(
%
)
0
20
40
60
80
100
 
Figure 3
Effect of polysaccharides on cell proliferation of NIH/
3T3 cells NIH/3T3 at 37°C in the absence () or presence
of 10 (), 100 () or 1000 µg/ml (♦ ) of Porphyridium sp.
polysaccharide or 100µg/ml of either dextran cells were
seeded at a concentration of 0.5 ×  106 cells per 9.6-cm2 plate
and incubated sulfate () or carrageenan (). Data are mean
± SD, (n = 4).
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The obtained differences between cell cultures infected
with either of these virus stocks (MuSV/MuLV or MuSV-
124) are due to the different characteristics of these infec-
tions. In the case of MuSV-124-infected cell cultures, the
inhibitory effect of Porphyridium sp. polysaccharide could
not be explained in terms of the inhibition of secondary
viral infections, since this virus yielded a virus nonproduc-
ing infection [30,31]. However, in MuSV/MuLV-infected
cultures, part of the inhibitory effect of the polysaccharide
against cell transformation could be a result of inhibiting
secondary viral infections, since the majority of the foci
that appeared in the cultures seemed to result from multi-
ple secondary infections by the progeny of the primary in-
fection.
Effect of time of addition of Porphyridium sp. polysaccha-
ride on release of progeny virus from MuSV/MuLV-infected 
cells
The algal polysaccharide probably exerted its effect by pre-
venting secondary infections, which were the major
source of foci scored in these cultures under our experi-
mental conditions. To determine whether the effect of the
polysaccharide was due to the arrest of virus release from
the primary infected cells or merely from blocking the es-
tablishment of secondary infections, the polysaccharide
was added at various times before and after infection, and
the release of progeny virus was followed by assaying viral
reverse transcriptase activity in aliquots taken from the
culture medium at different times post infection. The re-
sults presented in Fig. 4 showed that the infection cycle is
completed within 20–24 h after inoculation, this being
the time at which the appearance of the first progeny
could be detected. The polysaccharide had a significant in-
hibitory effect on the release of virus progeny even when
it was added 48 h after infection. Therefore, the significant
prevention of formation of malignant foci by the polysac-
charide at this late time was most likely due to its action
against the subsequent secondary infection cycle. These
results are in agreement with our suggestion that in MuSV/
MuLV-infected cultures, part of the inhibitory effect of the
polysaccharide against cell transformation could be a re-
sult of inhibiting secondary viral infections.
Effect of time of removal of Porphyridium sp. polysaccha-
ride on cell transformation
To determine whether it is necessary for Porphyridium sp.
polysaccharide to remain in the culture during the whole
time until scoring of foci, cells were treated with the
polysaccharide 2 h before infection and polysaccharide
was removed at various times after infection. Foci were
scored 12 days after infection. As can be seen from Table
4, about 75 and 65% of the transforming capacity of
MuSV-124 and MuSV/MuLV, respectively, were recovered
when the polysaccharide was removed at the time of infec-
tion. When Porphyridium sp. polysaccharide was removed
72 h post-infection, only 55% and 20% of transforming
capacity of MuSV-124 and MuSV/MuLV, respectively,
were recovered.
As a consequence of the different character of the infec-
tion by these two virus stocks, their focus-forming capaci-
ty responded quite differently to the timing of
polysaccharide addition and removal. In the case of
MuSV/MuLV infected cultures, focus formation was sig-
nificantly inhibited even when the polysaccharide was
added or removed at longer times after infection com-
pared to MuSV-124 infected cultures. These findings indi-
cate that the continuous presence of thepolysaccharide in
the culture medium after infection with the virus was es-
sential for full prevention of malignant transformation
Table 2: Effect of dosage of Porphyridium sp. polysaccharide on 
NIH/3T3 cell transformation by MuSV-124 and MuSV/MuLV
Porphyridium sp. 
polysaccharide (µg/ml)
Number of foci1
MuSV-124 MuSV/MuLV
02 0 0   ± 10 120 ± 8
51 5 0   ± 10 90 ± 7
10 110 ± 8 65 ± 5
50 15 ± 6 10 ± 3
100 0 0
250 0 0
1Mean of 5 cultures ± SD. Foci scored 14 days after infection.
Table 3: Effect of time of addition of Porphyridium sp. polysach-
aride on NIH/3T3 cell transformation
Timing of Porphyridiumsp. 
addition of polysaccharide
Number of foci1
MuSV-124 MuSV/MuLV
None 80 70
24 h before infection 0 0
2 h before infection 0 0
0 h at infection 0 0
2 h after infection 15 ± 46  ± 2
24 h after infection 50 ± 7 14 ± 4
48 h after infection 73 ± 6 30 ± 5
72 h after infection 75 ± 7 64 ± 6
1Means of five cultures ± SD Foci were scored 12 days after infection. 
h means hours.Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/8
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over the tested period (about two weeks). When the treat-
ment with the polysaccharide was terminated immediate-
ly post-infection (Table 4), there was a significant recovery
in the appearance of malignant transformed cells for all
tested concentrations of the polysaccharide. This reversi-
bility strongly suggests that the polysaccharide, partially at
least, exerted its inhibitory effect on a certain event occur-
ring after proviral integration. In addition, this reversibil-
ity could not be explained only by the possibility of
preventing viral reinfections by the polysaccharide be-
cause in the case of MuSV-124 infections there are no rei-
fections [30,31]. The inhibitory effect does not seem to be
mediated by interferon or by an interferon-like antiviral
state, since interferon has been found to inhibit certain
events occurring before proviral integration [31].
Our results do not rule out the possibility that at least part
of the inhibitory effect of the polysaccharide was due to
blocking some of the viral receptors, thus interfering with
the penetration of the virus into the cells. This possibility
was supported by our results showing that treatment of
the cells with the polysaccharide post-infection caused a
significant inhibition of cell transformation, but that this
inhibition was less impressive than that obtained when
treatment with the polysaccharide was started before or at
the time of infection (Table 3). This possibility is also in
agreement with various previous studies
[9,17,18,22,24,32] that suggested that sulfated polysac-
charides prevent early steps in the viral life cycle. In addi-
tion, some of our data not presented here showed that the
inhibitory effect of Porphyridium sp. polysaccharide on cell
malignant transformation by MuSV was not a result of a
direct interaction between the polysaccharide and the vi-
rus particles. In contrast, our previous data (29) showed a
strong interaction between Herpes simplex virus (HSV 1
and HSV-2) particles and Porphyridium sp. polysaccharide.
This contradiction could be due to differences in viral en-
velope composition. Herpes viruses envelope is positively
charged, whereas retroviruses are negatively charged.
Therefore, the sulfate groups of the polysaccharide could
easily interact with positively charged viruses.
Conclusions
The present data show that the red microalgal polysaccha-
rides profoundly inhibited retroviral malignant cell trans-
formation and retrovirus replication. Most effective
inhibitory activity of these polysaccarides on cell transfor-
mation was obtained when the cells were treated with
polysaccharide before or at the time of infection. These re-
sults support the possibility that at least part of the inhib-
itory effect of the polysaccharide was due to blocking
some of the viral receptors, thus interfering with the pen-
etration of the virus into the cells. On the other hand, the
reversibility of this inhibitory activity strongly suggests
that the polysaccharide exerted its inhibitory effect also on
Figure 4
Effect of time of Porphyridium sp. polysaccharide
addition on MuLV progeny release Polysaccharide (100
µg/ml) untreated cells (♦ ) or treated at the time of infection
(), 24 h () or 48 h (♦ ) postinfection (p.i.), were inocu-
lated with MuSV/MuLV. Two hours after inoculation, unad-
sorbed virus was removed by three washes, and the cells
were covered with fresh medium containing the polysaccha-
ride in all treated cultures. Virus release was followed by
assaying viral reverse transcriptase activity in aliquots taken
from the culture medium at various times after inoculation. h
means hours. Data are mean ± SD, (n = 4).
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Table 4: Focus formation after removal of Porphyridium sp. 
polysaccharide
Porphyridium sp. polysaccharide Number of foci1
MuSV-124 MuSV/MuLV
Not added 100 ± 67 0  ± 5
Not removed 0 0
Removed at:
0 h after infection 75 ± 76 5  ± 4
24 h after infection 64 ± 65 0  ± 5
72 h after infection 55 ± 20 ± 4
1Means of five cultures ± SD 100 µg/ml of Porphyridiumsp. polysach-
aride were added 2 h before infection and removed at the indicated 
times. Foci were scored 12 days postinfection. h means hours.Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/8
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a certain event occurring after proviral integration. Thus, it
appears that Porphyridium sp. polysaccharide has a plei-
otropic mode of action during the infection cycle of
MuSV. The exact steps (or step) during the viral replication
cycle that are affected by Porphyridium sp. polysaccharide
remain to be elucidated.
Materials and Methods
Cells and viruses
NIH/3T3 cells (mouse fibroblast cells) were grown at
37°C in RPMI medium supplemented with 10% new born
calf serum (NBCS) and the antibiotics penicillin, strepto-
mycin and neomycin. Clone 124 of TB cells chronically
releasing Moloney murine sarcoma virus (MuSV-124)
(31) was used to prepare a virus stock that contained an
approximately 30-fold excess of MuSV particles over
Moloney murine leukemia virus (MuLV) particles. MuLV
and MuSV used in this research were grown on NIH/3T3
cells. The virus concentration was determined by counting
the number of foci (ffu-focus-forming units) in the case of
MuSV and by the reverse transcriptase assay in the case of
MuLV.
Preparation and purification of microalgal polysaccharide
Polysaccharides produced from three species of red micro-
alga; Porphyridium sp., P. aerugineum and Rhodella reticula-
ta, were used in this study. The polysaccharides were
collected and purified as previously described [33]. Brief-
ly, these polysaccharides are produced and secreted into
the growth medium by the appropriate red microalgae.
The medium was collected, cells were removed by centrif-
ugation and the supernatant containing the polysaccha-
rides was dialyzed and lyophilized.
Cell infection and determination of viral infection
A monolayer of NIH/3T3 cells was grown in 9-cm2 tissue
culture plates and treated with 0.8 µg/ml of polybrene (a
cationic polymer required for neutralizing the negative
charge of the cell membrane) for 24 h before infection
with the virus. Free polybrene was then removed, and the
cells were incubated at 37°C for 2 h with the infecting vi-
rus (MuSV-124) at various concentrations in RPMI medi-
u m  c o n t a i n i n g  2 %  o f  N B C S .  T h e  u n a b s o r b e d  v i r u s
particles were removed, fresh medium containing 2%
NBCS was added, and the monolayers were incubated at
37°C. After 2–3 days, the cell cultures were examined for
the appearance of malignant transformed cells. The
amount of malignant transformed cells was expressed as
the percentage of transformed cells in the inspection field
or as the number of foci in the infected culture 10 days af-
ter infection.
Reverse transcriptase assay
Viral reverse transcriptase activity was assayed as previous-
ly described [34].
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